Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tourmaline Bio, Inc.

Get SEC filing alerts via email and in your feed for Tourmaline Bio, Inc.

TRML

Tourmaline Bio, Inc.

About Tourmaline Bio, Inc.

Tourmaline Bio, Inc. is a biotechnology company developing innovative medicines targeting immune and inflammatory diseases. Its lead candidate, pacibekitug, is a fully human monoclonal antibody that inhibits IL-6, a cytokine involved in autoimmune and inflammatory conditions. The company focuses on high unmet medical needs, advancing therapies for cardiovascular inflammation, thyroid eye disease, and other autoimmune disorders through clinical trials and strategic collaborations.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Tourmaline Bio, Inc.

1
1
Tourmaline Bio, Inc. Tourmaline Bio Reports $23.1 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

2
1
Tourmaline Bio, Inc. Tourmaline Bio Reports $22.97 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Tourmaline Bio, Inc. Tourmaline Bio Reports Significant Financial Developments, Raises $172.5 Million in Public Offering

Via official filing (AI summary) | over 1 year ago | 0 comments